Your browser doesn't support javascript.
loading
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Harrod, Alison; Lai, Chun-Fui; Goldsbrough, Isabella; Simmons, Georgia M; Oppermans, Natasha; Santos, Daniela B; Gyorffy, Balazs; Allsopp, Rebecca C; Toghill, Bradley J; Balachandran, Kirsty; Lawson, Mandy; Morrow, Christopher J; Surakala, Manasa; Carnevalli, Larissa S; Zhang, Pei; Guttery, David S; Shaw, Jacqueline A; Coombes, R Charles; Buluwela, Lakjaya; Ali, Simak.
Afiliação
  • Harrod A; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Lai CF; Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK.
  • Goldsbrough I; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Simmons GM; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Oppermans N; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Santos DB; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Gyorffy B; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Allsopp RC; Semmelweis University Department of Bioinformatics, H-1094 Budapest, Hungary and TTK Cancer Biomarker Research Group, H-1117, Budapest, Hungary.
  • Toghill BJ; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK.
  • Balachandran K; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK.
  • Lawson M; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Morrow CJ; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK.
  • Surakala M; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK.
  • Carnevalli LS; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK.
  • Zhang P; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK.
  • Guttery DS; Early Oncology R&D, AstraZeneca, Biomedical Campus, 1 Francis Crick Ave, Cambridge, CB2 0AA, UK.
  • Shaw JA; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK.
  • Coombes RC; Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK.
  • Buluwela L; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK.
  • Ali S; Department of Surgery & Cancer, Imperial College London, London, W12 0NN, UK. l.buluwela@imperial.ac.uk.
Oncogene ; 41(44): 4905-4915, 2022 10.
Article em En | MEDLINE | ID: mdl-36198774
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Oncogene Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Oncogene Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido